BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 12727974)

  • 1. The use of androgen receptor amino/carboxyl-terminal interaction assays to investigate androgen receptor gene mutations in subjects with varying degrees of androgen insensitivity.
    Ghali SA; Gottlieb B; Lumbroso R; Beitel LK; Elhaji Y; Wu J; Pinsky L; Trifiro MA
    J Clin Endocrinol Metab; 2003 May; 88(5):2185-93. PubMed ID: 12727974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discordant measures of androgen-binding kinetics in two mutant androgen receptors causing mild or partial androgen insensitivity, respectively.
    Shkolny DL; Beitel LK; Ginsberg J; Pekeles G; Arbour L; Pinsky L; Trifiro MA
    J Clin Endocrinol Metab; 1999 Feb; 84(2):805-10. PubMed ID: 10022458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disrupted amino- and carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity.
    Thompson J; Saatcioglu F; Jänne OA; Palvimo JJ
    Mol Endocrinol; 2001 Jun; 15(6):923-35. PubMed ID: 11376111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human androgen receptor mutation disrupts ternary interactions between ligand, receptor domains, and the coactivator TIF2 (transcription intermediary factor 2).
    Lim J; Ghadessy FJ; Abdullah AA; Pinsky L; Trifiro M; Yong EL
    Mol Endocrinol; 2000 Aug; 14(8):1187-97. PubMed ID: 10935543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An examination of how different mutations at arginine 855 of the androgen receptor result in different androgen insensitivity phenotypes.
    Elhaji YA; Wu JH; Gottlieb B; Beitel LK; Alvarado C; Batist G; Trifiro MA
    Mol Endocrinol; 2004 Aug; 18(8):1876-86. PubMed ID: 15118070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel mutation F826L in the human androgen receptor in partial androgen insensitivity syndrome; increased NH2-/COOH-terminal domain interaction and TIF2 co-activation.
    Wong HY; Hoogerbrugge JW; Pang KL; van Leeuwen M; van Royen ME; Molier M; Berrevoets CA; Dooijes D; Dubbink HJ; van de Wijngaart DJ; Wolffenbuttel KP; Trapman J; Kleijer WJ; Drop SL; Grootegoed JA; Brinkmann AO
    Mol Cell Endocrinol; 2008 Sep; 292(1-2):69-78. PubMed ID: 18656523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A naturally occurring mutation in the human androgen receptor of a subject with complete androgen insensitivity confers binding and transactivation by estradiol.
    Bonagura TW; Deng M; Brown TR
    Mol Cell Endocrinol; 2007 Jan; 263(1-2):79-89. PubMed ID: 17011702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial androgen insensitivity with phenotypic variation caused by androgen receptor mutations that disrupt activation function 2 and the NH(2)- and carboxyl-terminal interaction.
    Quigley CA; Tan JA; He B; Zhou ZX; Mebarki F; Morel Y; Forest MG; Chatelain P; Ritzén EM; French FS; Wilson EM
    Mech Ageing Dev; 2004; 125(10-11):683-95. PubMed ID: 15541764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel mutation in the human androgen receptor suggests a regulatory role for the hinge region in amino-terminal and carboxy-terminal interactions.
    Deeb A; Jääskeläinen J; Dattani M; Whitaker HC; Costigan C; Hughes IA
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3691-6. PubMed ID: 18697867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substitution of valine-865 by methionine or leucine in the human androgen receptor causes complete or partial androgen insensitivity, respectively with distinct androgen receptor phenotypes.
    Kazemi-Esfarjani P; Beitel LK; Trifiro M; Kaufman M; Rennie P; Sheppard P; Matusik R; Pinsky L
    Mol Endocrinol; 1993 Jan; 7(1):37-46. PubMed ID: 8446106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional analysis of a novel androgen receptor mutation, Q902K, in an individual with partial androgen insensitivity.
    Umar A; Berrevoets CA; Van NM; van Leeuwen M; Verbiest M; Kleijer WJ; Dooijes D; Grootegoed JA; Drop SL; Brinkmann AO
    J Clin Endocrinol Metab; 2005 Jan; 90(1):507-15. PubMed ID: 15486055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A G577R mutation in the human AR P box results in selective decreases in DNA binding and in partial androgen insensitivity syndrome.
    Nguyen D; Steinberg SV; Rouault E; Chagnon S; Gottlieb B; Pinsky L; Trifiro M; Mader S
    Mol Endocrinol; 2001 Oct; 15(10):1790-802. PubMed ID: 11579211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity.
    Elhaji YA; Stoica I; Dennis S; Purisima EO; Lumbroso R; Beitel LK; Trifiro MA
    Hum Mol Genet; 2006 Mar; 15(6):921-31. PubMed ID: 16449235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligospermic infertility associated with an androgen receptor mutation that disrupts interdomain and coactivator (TIF2) interactions.
    Ghadessy FJ; Lim J; Abdullah AA; Panet-Raymond V; Choo CK; Lumbroso R; Tut TG; Gottlieb B; Pinsky L; Trifiro MA; Yong EL
    J Clin Invest; 1999 Jun; 103(11):1517-25. PubMed ID: 10359561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partial androgen insensitivity and correlations with the predicted three dimensional structure of the androgen receptor ligand-binding domain.
    Yong EL; Tut TG; Ghadessy FJ; Prins G; Ratnam SS
    Mol Cell Endocrinol; 1998 Feb; 137(1):41-50. PubMed ID: 9607727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2).
    Berrevoets CA; Doesburg P; Steketee K; Trapman J; Brinkmann AO
    Mol Endocrinol; 1998 Aug; 12(8):1172-83. PubMed ID: 9717843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amino acid substitutions in the hormone-binding domain of the human androgen receptor alter the stability of the hormone receptor complex.
    Marcelli M; Zoppi S; Wilson CM; Griffin JE; McPhaul MJ
    J Clin Invest; 1994 Oct; 94(4):1642-50. PubMed ID: 7929841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription.
    Song LN; Herrell R; Byers S; Shah S; Wilson EM; Gelmann EP
    Mol Cell Biol; 2003 Mar; 23(5):1674-87. PubMed ID: 12588987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An androgen receptor mutation in the direct vicinity of the proposed C-terminal alpha-helix of the ligand binding domain containing the AF-2 transcriptional activating function core is associated with complete androgen insensitivity.
    Peters I; Weidemann W; Romalo G; Knorr D; Schweikert HU; Spindler KD
    Mol Cell Endocrinol; 1999 Feb; 148(1-2):47-53. PubMed ID: 10221770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor.
    Doesburg P; Kuil CW; Berrevoets CA; Steketee K; Faber PW; Mulder E; Brinkmann AO; Trapman J
    Biochemistry; 1997 Feb; 36(5):1052-64. PubMed ID: 9033395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.